Compare Corning Incorporated (GLW) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Corning Incorporated vs Vertex Pharmaceuticals Incorporated — how do they compare? Corning Incorporated trades at $158.08 (market cap $150.10B), while Vertex Pharmaceuticals Incorporated trades at $482.07 (market cap $121.09B). The key difference: Corning Incorporated is the larger of the two by market cap, and Corning Incorporated pays a 0.64% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals.
| GLW | VRTX | |
|---|---|---|
Market Cap | $150.10B | $121.09B |
Sector | Technology | Health |
52-Week High | $255.79 | $529.59 |
52-Week Low | $52.97 | $366.54 |
Enterprise Value | $158.27B | $115.83B |
Dividend Yield | 0.64% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Corning (GLW) trades at $187.68, up 2.36% today, with a neutral technical signal and bearish moving averages. Recent earnings beats and strong 2025 results, including $15.63B revenue and $1.60B net income, highlight fundamental strength. The stock has retreated from its June 2026 peak of $271.38, with analyst consensus pointing to a $210.10 price target. Key support lies at $185, with resistance at $191.
The outlook remains positive due to AI-driven optical communication demand and partnerships with NVIDIA and Amazon. Risks include market volatility and competitive pressures, but institutional sentiment is bullish with 54% buy ratings. Upside potential exists if the company maintains its earnings momentum and capitalizes on infrastructure spending trends.
Vertex Pharmaceuticals (VRTX) trades at $476.31, down 0.82% over 24 hours, with a bullish technical signal despite mixed moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $4.47, and maintains robust profitability with a net income margin of 35.51%. Recent news highlights a $10 billion acquisition of Crinetics Pharmaceuticals, aimed at expanding its endocrinology portfolio with potential peak sales of over $5 billion.
The outlook remains positive with analyst consensus favoring a buy rating (83.92%) and a price target of $538, suggesting 13% upside. Key risks include integration challenges from the Crinetics deal and reliance on cystic fibrosis treatments, while strong cash flow and earnings growth support long-term value.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Corning Incorporated
Corning Inc is a leader in materials science, specializing in the production of glass, ceramics and optical fiber. The firm supplies its products for a wide range of applications, from flat-panel displays in televisions to gasoline particulate filters in automobiles to optical fiber for broadband access, with a leading share in many of its end markets.
Read more on GLW →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
